Jiangsu Hengrui Medicine Co., Ltd (SHA: 600276), a prominent pharmaceutical company based in China, has been granted approval by the National Medical Products Administration (NMPA) to initiate a clinical study for HRS-5965, a novel therapeutic targeting primary or secondary glomerular diseases. The conditions include IgA nephropathy, idiopathic membranous nephropathy, C3 nephropathy, and lupus nephritis, which are mediated by the complement system.
HRS-5965 is designed to inhibit complement system-mediated hemolysis by curbing the over-activation of the complement system. Preclinical studies have demonstrated that HRS-5965 significantly suppresses complement-mediated hemolysis in various models, while also exhibiting a promising safety profile. Currently, no similar product has been approved for marketing in China, positioning HRS-5965 as a potential first-in-class therapy. Hengrui has invested RMB 40.16 million (USD 5.86 million) in the development of HRS-5965 to date.- Flcube.com
